Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin + orlistat + trimetazidine with second-line therapy for advanced liver cancer
ChiCTR2300074976Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of simvastatin, orlistat and trimetazidine in liver cancer, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Objective Response Rate. Started Sep 2023; status: recruiting.
02
Drugs
simvastatinorlistattrimetazidine
03
Conditions
liver cancer
Beyond the preview
Go deeper on ChiCTR2300074976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074976.